Advertisement

Molecular Farming for Production of Biopharmaceuticals and Edible Vaccines in Plants

  • Ajitabh Bora
  • Hemanta Kumar Gogoi
  • Vijay Veer
Chapter

Abstract

Production of recombinant proteins such as edible vaccines, recombinant subunit vaccines, antibodies and other medical proteins in plants is referred to as molecular farming. Plants, as expression platform, have several advantages over mammalian or microbial systems such as low cost of production, fast scalability, absence of pathogenic microbes and their capability to synthesise complex proteins. This involves identification and isolation of the gene of a pathogen encoding antigenic protein and preparation of a suitable construct followed by its introduction to a suitable plant host system either through Agrobacterium-mediated or direct gene transfer technique for expression of the protein of interest. The plant parts of the transgenic plant containing the antigen are fed raw or the protein is extracted and administered. The cultivation of these plants needs to be done in a greenhouse or under in vitro condition in order to negate environmental and biosafety issues. Biofarming offers great opportunity to the pharmaceutical industry for production and supply of medicines at an affordable cost, particularly to the developing countries.

Keywords

Transgenic Plant Recombinant Protein Subunit Vaccine Transgenic Potato Merozoite Surface Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Ball JM, Graham DY, Opekum AR et al (1999) Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterol 117:40–48CrossRefGoogle Scholar
  2. Barta A, Sommengruber K, Thompson D et al (1986) The expression of a napoline synthase human growth hormone chimeric gene in transformed tobacco and sunflower callus tissue. Plant Mol Biol 6:347–357CrossRefPubMedGoogle Scholar
  3. Bevan MW, Flavell RB, Chilton MD (1983) A chimaeric antibiotic resistance gene as a selectable marker for plant cell transformation. Nature 304:184–187CrossRefGoogle Scholar
  4. Blanas E, Carbone FR, Allison J et al (1996) Induction of autoimmune diabetes by oral administration of auto antigen. Science 274:1707–1709CrossRefPubMedGoogle Scholar
  5. Chong DK, Langridge WHR (2000) Expression of full length bioactive anti-microbial human lactoferrin in potato plants. Transl Res 9:71–78CrossRefGoogle Scholar
  6. Chong DK, Roberts W, Arakawa T et al (1997) Expression of the human milk protein β-casein in transgenic potato plants. Transl Res 6:289–296CrossRefGoogle Scholar
  7. Christou P (1996) Transformation biotechnology. Trends Plant Sci 1:423–431CrossRefGoogle Scholar
  8. Chu L, Robinson DK (2001) Industrial choices for protein production by large scale cell culture. Curr Opin Biotechnol 12:180–187CrossRefPubMedGoogle Scholar
  9. Conrad U, Fiedler U (1994) Expression of engineered antibodies in plant cells. Plant Mol Biol 26:1023–1050CrossRefPubMedGoogle Scholar
  10. Daniell H, Streatfield SJ, Wyckoff K (2001) Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines. Trends Plant Sci 6:219–226CrossRefPubMedGoogle Scholar
  11. Daniell H, Khan MS, Allison L (2002) Milestone in the chloroplast genetic engineering: an environmentally friendly era in biotechnology. Trends Plant Sci 7:84–91PubMedCentralCrossRefPubMedGoogle Scholar
  12. Dohutia C (2014) The wonders of pharming. Horizon in The Assam Tribune. p 2Google Scholar
  13. Domansky N (1995) Organ-specific expression of hepatitis B surface antigen in potato. Biotechnol Lett 17:863–866CrossRefGoogle Scholar
  14. Fischer R, Emans N (2000) Molecular farming of pharmaceutical proteins. Transl Res 9:279–299CrossRefGoogle Scholar
  15. Fischer R, Stoger E, Schillberg S et al (2004) Plant-based production of biopharmaceuticals. Curr Opin Plant Biol 7:125–128Google Scholar
  16. Fraley RT, Rogers SG, Horsch RB et al (1983) Expression of bacterial genes in plant cells. Proc Natl Acad Sci USA 80:4803–4807PubMedCentralCrossRefPubMedGoogle Scholar
  17. Franken E, Teuschel U, Hain R (1997) Recombinant proteins from transgenic plants. Curr Opin Biotechnol 8:411–416CrossRefPubMedGoogle Scholar
  18. Gelvin SB (2003) Agrobacterium mediated plant transformation: the biology behind the “gene-jockeying tool”. Microbiol Mol Biol Rev 67:16–23PubMedCentralCrossRefPubMedGoogle Scholar
  19. Gidding G (2001) Transgenic plants as protein factories. Curr Opin Biotechnol 12:450–454CrossRefGoogle Scholar
  20. Gidding G, Allison G, Brooks D et al (2000) Transgenic plants as factories for biopharmaceuticals. Nat Biotechnol 18:1151–1155CrossRefGoogle Scholar
  21. Goldstein DA, Thomas JA (2004) Biopharmaceuticals derived from genetically modified plants. Q J Med 97:705–716CrossRefGoogle Scholar
  22. Hiatt A, Cafferkey R, Bowdish K (1989) Production of antibodies in transgenic plants. Nature 342:76–78CrossRefPubMedGoogle Scholar
  23. Hood EE (2002) From green plants to industrial enzymes. Enzyme Microb Technol 30:279–283CrossRefGoogle Scholar
  24. Hood EE, Witcher DR, Maddock S et al (1997) Commercial production of avidin from transgenic maize: characterization of transformant, production, processing, extraction and purification. Mol Breed 3:291–306CrossRefGoogle Scholar
  25. Horn ME, Woodard SL, Howard JA (2004) Plant molecular farming: systems and products. Plant Cell Rep 22:711–720CrossRefPubMedGoogle Scholar
  26. Houdebaine LM (2000) Transgenic animal bioreactors. Transgenic Res 9:305–320CrossRefGoogle Scholar
  27. Huang Z, Dry I, Webstar D et al (2001) Plant-derived measles virus hemagglutinin protein induces neutralizing antibodies in mice. Vaccine 19:2163–2171CrossRefPubMedGoogle Scholar
  28. Jefferson RA, Kavanaugh TA, Bevan MW (1987) GUS fusions: β-glucuronidase as a sensitive and versatile gene fusion marker in higher plants. EMBO J 6:3901–3907PubMedCentralPubMedGoogle Scholar
  29. Kapusta J, Modelska A, Figlerowicz M et al (1999) A plant derived edible vaccine against hepatitis B virus. FASEB J 13:1796–1799PubMedGoogle Scholar
  30. Kusnadi AR, Hood EE, Witcher DR et al (1998) Production and purification of two recombinant proteins from transgenic corn. Biotechnol Prog 14:149–155CrossRefPubMedGoogle Scholar
  31. Lal P, Ramachandran VG, Goyal R et al (2007) Edible vaccines: current status and future. Indian J Med Microbiol 25:93–102CrossRefPubMedGoogle Scholar
  32. Larrick JW, Thomas DW (2001) Producing proteins in transgenic plants and animals. Curr Opin Biotechnol 12:411–418CrossRefPubMedGoogle Scholar
  33. Leben M, Johansson S, Osek J (1993) Large-scale production of vibrio cholera toxin B subunit for use in oral vaccines. Biotechnology (N Y) 11:1574–1578CrossRefGoogle Scholar
  34. Lee RWH, Strommer J, Hodgins D et al (2001) Towards development of an edible vaccine against Bovine Pneumonic pasteurellosis using transgenic white clover expressing a Mannheimia haemolytica A1, Leukotoxin 50 fusion protein. Infect Immun 69:5786–5793PubMedCentralCrossRefPubMedGoogle Scholar
  35. Ma JKC, Hiatt A, Hein M et al (1995) Generation and assembly of secretory antibodies in plants. Science 268:716–719CrossRefPubMedGoogle Scholar
  36. Ma SW, Zhao DL, Yin ZQ et al (1997) Transgenic plants expression auto antigens fed to mice to induce oral immune tolerance. Nat Med 3:793–796CrossRefPubMedGoogle Scholar
  37. Ma JKC, Drake PMW, Christou P (2003) The production of recombinant pharmaceutical proteins in plants. Genetics 4:794–805PubMedGoogle Scholar
  38. Marquet-Blouin E, Bouche FB, Steinmetz A et al (2003) Neutralizing immunogenicity of transgenic carrot (Daucus carota L.)- derived measles virus hemagglutinin. Plant Mol Biol 51:458–469CrossRefGoogle Scholar
  39. Marsa L (1994) Enhancing the benefits of nature. Omni 16:14Google Scholar
  40. Mason HS, Arntzen CJ (1995) Transgenic plant as vaccine production system. Trends Biotechnol 13:388–392CrossRefPubMedGoogle Scholar
  41. Mason HS, Lam DMK, Arntzen CJ (1992) Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci USA 89:11745–11749PubMedCentralCrossRefPubMedGoogle Scholar
  42. Mason HS, Haq FA, Clement JD (1998) Edible vaccine protects mice against Escherichia Coli het labile anterotoxin (LT): potatoes expression a synthetic LT-B Gene. Vaccine 16:1336–1343CrossRefPubMedGoogle Scholar
  43. Mayfield SP, Franklin SE, Lerner RA (2003) Expression and assembly of a fully active antibody in algae. Proc Natl Acad Sci USA 100:438–442PubMedCentralCrossRefPubMedGoogle Scholar
  44. Mishra N, Gupta PN, Khatri K et al (2008) Edible vaccines: a new approach to oral immunization. Indian J Biotechnol 7:283–294Google Scholar
  45. Pant G, Sanjana WK (2014) Edible vaccines: a boon to medical science. Intl J Curr Agric Res 3:76–80Google Scholar
  46. Richter L, Mason HS, Arntxen CJ (1996) Transgenic plants created for oral immunization against diarrheal diseases. Travel Med 3:52–56CrossRefGoogle Scholar
  47. Rudzik R, Claney RL, Perey YE et al (1975) Repopulation with IgA-containing cells of bronchial and intestinal lamina propria after transfer of homologous Peyer’s patch and bronchial lymphocytes. J Immunol 144:1599Google Scholar
  48. Ruggiero F, Exposito JY, Bournat P et al (2000) Triple helix assembly and processing of human collagen produced in transgenic tobacco plants. FEBS Lett 469:132–136CrossRefPubMedGoogle Scholar
  49. Scheller J, Guhrs KH, Grosse F, Conrad U (2001) Production of spider silk proteins in tobacco and potato. Nat Biotechnol 19:573–577CrossRefPubMedGoogle Scholar
  50. Schillberg S, Fischer R, Emans N (2003) Molecular farming of antibodies in plants. Naturwissenschften 0:145–155Google Scholar
  51. Schwartz JR (2001) Advances in Escherichia coli production of therapeutic proteins. Curr Opin Biotechnol 12:195–201CrossRefGoogle Scholar
  52. Shah CP, Trivedi MN, Vachhani UD, Joshi V (2011) Edible vaccine: a better way for immunization. Int J Curr Pharma Res 3:53–56Google Scholar
  53. Sijmons PC, Dekker BM, Schrammeijer B et al (1990) Production of correctly processed human serum albumin in transgenic plants. Biotechnology (N Y) 8:217–221CrossRefGoogle Scholar
  54. Singh BD (2009) Biotechnology- expanding horizons. Kalyani Publishers, LudhianaGoogle Scholar
  55. Stoger E, Sack M, Perrin Y et al (2000) Practical considerations for pharmaceutical antibody production in different crop systems. Mol Breed 9:149–158CrossRefGoogle Scholar
  56. Tacket CO, Mason HS, Losonsky G et al (1998) Immunogenicity in humans of a recombinant bacterial antigen delivered in transgenic potato. Nat Med 4:607–609CrossRefPubMedGoogle Scholar
  57. Veluthambi K, Gupta AK, Sharma A (2003) The current status of plant transformation technologies. Curr Sci Ind 84:368–380Google Scholar
  58. Wang L, Goshnick MW, Copllel RL (2004) Oral immunization with a combination of plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge. Infect Immun 72:6172–6175PubMedCentralCrossRefPubMedGoogle Scholar
  59. Washam C (1997) Biotechnology creating edible vaccines. Ann Intern Med 127:499CrossRefPubMedGoogle Scholar
  60. Webster DE, Thomas DE, Strugnell RA et al (2002) Appetizing solutions: an edible vaccine for measles. Med J Aust 176:434–337PubMedGoogle Scholar
  61. Wilde CD, Peeters K, Jacobs A et al (2002) Expression of antibodies and Fab fragments in transgenic potato plants: a case study for bulk production in crop plants. Mol Breed 9:271–282CrossRefGoogle Scholar
  62. Witcher DR, Hood EE, Petersen D et al (1998) Commercial production of bglucuronidase (GUS): a model system for the production of proteins in plants. Mol Breed 4:301–312CrossRefGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  1. 1.Defence Research Laboratory (Defence Research and Development Organisation)TezpurIndia

Personalised recommendations